News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Neeraj Agarwal, MD, Huntsman Cancer Institute

Articles by Neeraj Agarwal, MD, Huntsman Cancer Institute

Future of Treating mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Treating Patients With mRCC Beyond Second-Line

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Strategies for Switching From Frontline Therapy to Second-Line Therapy in mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Clinical Trials Shaping Treatment in Relapsed/Refractory mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Choosing Second-Line Therapy in Treatment of mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Tailored Therapy Approaches for Upfront mRCC Treatment

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Treating Side Effects of Therapy for mRCC with Steroids

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Evaluating Safety Profiles of Upfront Regimens for mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Choosing Upfront Therapy for mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

CheckMate 9ER: Phase 3 Trial of Frontline Nivolumab + Cabozantinib

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Evaluating Long-Term Follow-Up Data for Treatment of mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Patient Factor Consideration for Treatment of mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Applying Clinical Trial Data for Treatment of mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Clinical Trials Defining the NCCN Guidelines for Frontline Treatment of mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Evaluation of Risk for Frontline Advanced/Metastatic Clear Cell RCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Latest Updated Articles

Clinical Trials Defining the NCCN Guidelines for Frontline Treatment of mRCC
Published: July 23rd 2020 | Updated:
$Clinical Trials Shaping Treatment in Relapsed/Refractory mRCC$
Clinical Trials Shaping Treatment in Relapsed/Refractory mRCC
Published: July 23rd 2020 | Updated:
Tailored Therapy Approaches for Upfront mRCC Treatment
Published: July 23rd 2020 | Updated:
Patient Factor Consideration for Treatment of mRCC
Published: July 23rd 2020 | Updated:
Future of Treating mRCC
Published: July 23rd 2020 | Updated:
Evaluation of Risk for Frontline Advanced/Metastatic Clear Cell RCC
Published: July 23rd 2020 | Updated:

Trending on OncLive

Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma

Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma

FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care

FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL

Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies